Kiniksa Pharmaceuticals International, plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Kiniksa Pharmaceuticals International, plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $677.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $423.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $270.26M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $220.18M | Feb 25, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $677.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $423.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $270.26M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $220.18M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $38.54M | Feb 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.01M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($43.19M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $14.08M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $183.36M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($157.92M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($161.38M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($161.87M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($103.23M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($64.87M) | Mar 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.22M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($45.62M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($25.20M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $9.77M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($156.64M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($157.36M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($169.96M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($108.16M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($65.40M) | Mar 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.85M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $111.62M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $76.10M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $65.49M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $99.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $112.04M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $135.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $86.60M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $56.36M | Mar 12, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $168.01M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $129.43M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $97.95M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $85.95M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $45.32M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $34.96M | Feb 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.99M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $25.69M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $13.30M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.81M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($126.30M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($136.53M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($158.37M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($81.01M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($50.22M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $277.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $130.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $105.0K | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $415.0K | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $283.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $3.20M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $5.29M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $69.0K | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $763.63M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $580.55M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $526.32M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $459.67M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $232.80M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $349.46M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $254.53M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $321.97M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $47.49M | Mar 12, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.03M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $142.12M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $87.48M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $63.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $47.76M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $37.53M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $29.11M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $42.70M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $17.43M | Mar 12, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.61M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $438.44M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $438.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $396.15M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $185.04M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $311.94M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $225.42M | Mar 2, 2023 |
| FY2021 | Dec 31, 2018 | $279.27M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | ($89.71M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2016 | ($25.73M) | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($462.14M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($521.14M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($477.95M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($492.03M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($675.40M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($517.47M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($356.09M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($194.23M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($91.00M) | Mar 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $183.58M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $107.95M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $122.72M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $122.47M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $114.04M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $46.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $71.98M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $45.56M | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 24, 2022 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 12, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 12, 2019 |